Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMPO4M1)

Drug Name
Paquinimod Drug Info
Synonyms ABR-215757; ABR-25757; Project 57-57, Active Biotech
Indication
Disease Entry ICD 11 Status REF
Lupus 4A40 Phase 2 [1]
Cross-matching ID
PubChem CID
54684617
CAS Number
CAS 248282-01-1
TTD Drug ID
DMPO4M1

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Calgranulin B (S100A9) TT0TMQG S10A9_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Calgranulin B (S100A9) DTT S100A9 7.913 5.182 6.785 6.88
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Lupus
ICD Disease Classification 4A40
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Calgranulin B (S100A9) DTT S100A9 2.86E-03 -1.43 -0.9
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01487551) An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod). U.S. National Institutes of Health.
2 Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis. Ann Rheum Dis. 2015 Dec;74(12):2254-8.